Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maike Stegen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Stefanie Klenke

    Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Essen, Deutschland

    4 shared publications
  • Thorsten Brenner

    Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Essen, Deutschland

    4 shared publications
  • Celine Nowak

    Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Essen, Deutschland

    2 shared publications
  • Hagen S. Bachmann

    From the Institute of Pharmacology and Toxicology, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University, Witten, Germany (HSB, DJ, LW), the Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany (MS, TB), the Evangelisches Klinikum Niederrhein, Duisburg, Germany (SK)

    2 shared publications
  • Ulrich Hermann Frey

    Department of Anaesthesiology, Intensive Care, Pain and Palliative Medicine, Marien Hospital Herne, Ruhr University Bochum, Hölkeskampring 40, Herne, 44625, Germany.

    2 shared publications
  • Ahmed Mohamed

    From the Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen (MS, GB, AM, BB, TB, SK), and Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research (ZBAF), Witten/Herdecke University, Witten, Germany (HSB)

    1 shared publication

Latest Publications

  • Vorteile einer standardisierten PONV-Prophylaxe

    by Maike Stegen, Celine Nowak, Thorsten Brenner, Stefanie Klenke

    Zusammenfassung Hintergrund Das postoperative Auftreten von Übelkeit und Erbrechen (postoperativ nausea and vomiting, PONV) ist aktuell die häufigste Nebenwirkung einer Narkose und wird von Betroffenen als stark einschränkend eingeschätzt. Die Berücksichtigung einer adäquaten PONV-Prophylaxe ist ein Qualitätskriterium moderner Narkoseführung. In unserer Klinik wurde eine Standard Operating Procedure (SOP) zur präoperativen Einschätzung des Risikos für PONV anhand des Apfel-Scores und zu deren strukturierter Prophylaxe und Therapie eingeführt. Fragestellung 1. Findet die SOP im klinischen Alltag ihre Umsetzung? 2. Welche Auswirkungen hat die SOP-konforme Prophylaxe in Bezug auf das Auftreten von PONV im Vergleich zu nicht-SOP-konformer Behandlung? Methoden In dieser Studie wurden retrospektiv 2000 Narkosedaten von Patienten, die sich einer elektiven Operation in Vollnarkose unterzogen, aus dem Zeitraum von September 2022 bis Juni 2023 bezüglich der Kongruenz und Auswirkungen einer im September 2022 neu eingeführten PONV-SOP ausgewertet. Ergebnisse Es wurden Narkosedaten von 1880 erwachsenen und 120 pädiatrischen Patienten untersucht. Bei den erwachsenen Patienten war die Adhärenz an das PONV-SOP-Schema mit 46,3 % gering. Die SOP-konforme Prophylaxe führte dennoch zu einer relativen Risikoreduktion der PONV-Inzidenz um 29 % sowie zu einer Reduktion der antiemetischen Bedarfsmedikation um 26 % im Vergleich zu einer Nicht-SOP-konformen Therapie. Die Wahrscheinlichkeit für eine SOP-konforme Prophylaxe stieg mit der Anzahl der Risikofaktoren gemäß dem Apfel-Score (p < 0,001) sowie bei expliziter präoperativer Angabe des Apfel-Scores in der anästhesiologischen Vorplanung (p < 0,001). Schlussfolgerung Die Einführung einer PONV-SOP stellt eine effektive Maßnahme zur PONV-Prophylaxe dar. Patienten profitierten hinsichtlich des Auftretens von PONV und der Notwendigkeit von antiemetischer Bedarfsmedikation von einer SOP-konformen Behandlung.


  • Association of the dopamine D2 receptor polymorphism rs1800497 with postoperative nausea and vomiting

    by Hagen S. Bachmann, Maike Stegen, Dominik Jung, Lea Weber, Thorsten Brenner, Stefanie Klenke

  • Open Access

    Association of the dopamine D2 receptor gene SNP rs1800497 with postoperative nausea and vomiting

    by Maike Stegen, Hagen S. Bachmann, Grazina Belani, Ahmed Mohamed, Björn Breuing, Thorsten Brenner, Stefanie Klenke

    BACKGROUND: Postoperative nausea and vomiting (PONV) are the most frequent complications in the context of anaesthesia. Several studies suggest a contribution of genetic traits to PONV disposition. Single nucleotide polymorphisms (SNPs) located in the cholinergic receptor muscarinic 3 gene CHRM3 (rs2165870) and the potassium voltage-gated channel subfamily B member 2 KCNB2 (rs349358) have been described as independent risk factors for the occurrence of PONV. In addition, further SNPs might be associated with an increased PONV risk, for example a dopamine D2 receptor (DRD2) SNP (rs1800497). OBJECTIVE: The primary aim of our study was the development of a new PONV prediction score which includes genetic information of SNPs in the genes CHRM3 and KCNB2, which have been already associated with PONV. The secondary aim of our study was to investigate the association of five additional SNPs with PONV. DESIGN: Prospective cohort study. SETTING: Single centre study in Germany. RESULTS: We could not establish a new PONV prediction score that includes genetic information, due to limited association of the KCNB2 SNP and CHRM3 SNP with PONV. Interestingly, the GA and AA genotypes of the DRD2 rs1800497 in the dopamine D2 receptor gene were associated with PONV 24 h postoperatively, with a relative risk (RR) of GA/AA genotype vs. GG genotype of 1.5 [95% confidence interval (CI) 1.06 to 2.01, P = 0.02]. This association was independent from the Apfel score in a multivariate logistic regression analysis (RR 1.4, 95% CI 1.03 to 1.90, P = 0.03). CONCLUSION: The construction of a new PONV prediction score including genetic information was not possible due to limited association of the CHRM3 and KCNB2 SNPs. However, the DRD2 GA and AA genotypes (rs1800497) were associated with PONV and this SNP might be a future candidate for further validation studies aiming for molecular-derived PONV prediction models. TRIAL REGISTRATION: German Clinical Study Register – DRKS00021051.


  • Open Access

    The Role of G Protein-Coupled Receptor Kinase 6 Regulation in Inflammation and Pain

    by Maike Stegen, Ulrich H. Frey

    The G protein-coupled receptor kinase 6 is associated with inflammation and pathological pain. Impairment of GRK6 expression was described in chronic inflammatory diseases such as rheumatoid arthritis and this was shown to be accompanied by an imbalance of downstream signaling pathways. Here, we discuss novel aspects of GRK6 interaction and its impact upon hyperalgesia and inflammatory processes. In this review, we compile important findings concerning GRK6 regulation for a better pathophysiological understanding of the intracellular interaction in the context of inflammation and show clinical implications—for example, the identification of possible therapy goals in the treatment of chronic inflammatory hyperalgesia.


  • Open Access

    Characterization of the G protein-coupled receptor kinase 6 promoter reveals a functional CREB binding site

    by Maike Stegen, Andrea Engler, Crista Ochsenfarth, Iris Manthey, Jürgen Peters, Winfried Siffert, Ulrich H. Frey

    Background: G protein-coupled receptor kinase 6 (GRK6) is part of the G protein-coupled receptor kinase family, whose members act as key regulators of seven-transmembrane receptor signalling. GRK6 seems to play a role in regulation of inflammatory processes, but mechanisms of transcriptional regulation of GRK6 expression in inflammatory cell lines have not been characterized. Protein kinase C (PKC) signalling is also involved in inflammatory regulation and an impact of PKC activation on GRK6 protein expression was described previously. Thus, the aim of this study was to 1) characterize theGRK6promoter, and 2) investigate a potential influence of PKC on GRK6 expression.Methods: Five deletion constructs of theGRK6promoter were cloned. After transient transfection into a human T cell line, promoter activity was assessed using luciferase reporter gene assays. Putative transcription factor binding sites were identified, mutated, and binding was investigated using electrophoretic mobility shift assays (EMSA). Following stimulation with a PKC activator, GRK6 expression on mRNA and protein levels was assessed by reverse transcriptase qPCR and Western blots.Results: Investigation of theGRK6promoter revealed a putative cAMP responsive element (CRE), whose mutation led to decreased promoter activity (p = 0.0006). Functionality of the CRE binding protein (CREB) binding site was verified in EMSA blots. Stimulation with a PKC activator resulted in decreasedGRK6promoter activity (p = 0.0027), mRNA (p = 0.04) and protein expression.Conclusion: We characterized the humanGRK6promoter and identified promoter activity to be influenced by a CREB binding site. PKC might be one determinant contributing to altered GRK6 expression.